美沙拉嗪对2，4，6-三硝基苯磺酸诱导溃疡性结肠炎大鼠脾脏组织NF—κBp65表达的影响

目的 探讨美沙拉嗪对2,4,6-三硝基苯磺酸（TNBS）诱导的溃疡性结肠炎大鼠脾脏组织NF-κB p65表达的影响.方法 将42只SD大鼠随机分为空白对照组、结肠炎模型组和美沙拉嗪治疗组,每组各14只.除空白对照组外,其他两组均应用TNBS灌肠制作溃疡性结肠炎大鼠模型;模型建成2d后,空白对照组和结肠炎模型组均用蒸馏水、美莎拉嗪治疗组用美莎拉嗪蒸馏水混悬液3 mL灌胃;连续灌胃15 d后取脾脏组织,采用RT-PCR法检测NF-κB p65 mRNA,Western blot法检测NF-κB p65蛋白.结果 与空白对照组比较,结肠炎模型组NF-κB p65 mRNA、蛋白表达均升高（P均＜0.05）;与结肠炎模型组比较,美沙拉嗪治疗组NF-κB p65 mRNA、蛋白均下降（P均＜0.05）.结论 美沙拉嗪能通过下调TNBS诱导的溃疡性结肠炎大鼠脾脏组织NF-κB p65的表达,发挥治疗溃疡性结肠炎的作用.     

美沙拉嗪治疗老年溃疡性结肠炎的临床效果观察

目的探讨美沙拉嗪治疗老年溃疡性结肠炎(UC)的临床效果。方法选择该院收治的68例老年UC患者随机分为观察组和对照组各34例,其中使用美沙拉嗪治疗的为观察组,使用柳氮磺吡啶治疗的为对照组。比较两组患者治疗前后临床症状、结肠镜检查结果、大便次数及肝肾功能的变化。结果观察组患者的总有效率为94.1%,对照组为79.4%,观察组治疗效果优于对照,差异有统计学意义(P0.05);观察组不良反应发生率为8.8%,对照组为29.4%,差异有统计学意义(P0.05)。结论美沙拉嗪治疗老年UC具有明显的治疗效果,并且药物的不良反应低,安全性较高。     

美沙拉嗪缓释片联合低分子肝素治疗溃疡性结肠炎的效果及对高凝状态影响

目的 探讨美沙拉嗪缓释片联合低分子肝素治疗溃疡性结肠炎的效果及对高凝状态的影响.方法 选择60例溃疡性结肠炎患者,按照随机数字表法分为两组,每组30例.对照组给予美沙拉嗪缓释片,观察组给予美沙拉嗪缓释片+低分子肝素,比较两组的总有效率、症状评分、血清炎症因子指标、血液流变学指标、不良反应发生率.结果 治疗2周后,观察组...     

美沙拉嗪对溃疡性结肠炎患者血清白细胞介素-6、白细胞介素-8及肿瘤坏死因子-α的影响

目的探讨美沙拉嗪治疗溃疡性结肠炎(UC)的疗效及对血清白细胞介素(IL)-6、IL-8及肿瘤坏死因子-α(TNF-α)的影响。方法选择40例活动期UC患者为观察组,选取与观察组相匹配的30名健康志愿者作为对照组。观察组应用美沙拉嗪缓释颗粒治疗6周,观察治疗效果,并比较2组血清IL-6、IL-8及TNF-α水平的差异。结果治疗6周后,观察组治疗总有效率为90.0%(36/40),不良反应发生率为2.5%(1/40);观察组治疗前血清IL-6、IL-8及TNF-α水平较健康对照组明显升高(P<0.01);观察组治疗后血清IL-6、IL-8及TNF-α水平均较治疗前明显下降(P<0.01)。结论 UC患者血清IL-6、IL-8及TNF-α等炎性因子水平明显升高,美沙拉嗪可有效下调其水平,获得较好的治疗效果,并具有较好的用药安全性。     

Successful treatment with topical mesalazine for a patient with intractable crohn’s colitis

A 32‐year‐old woman was admitted to our hospital for intractable Crohn’s disease. Crohn’s colitis was diagnosed at another hospital in August 1999. She had been successfully treated with oral mesalazine and an elemental diet. In March 2000, she had been admitted to the previous hospital for her third flare up of symptoms. She responded to oral mesalazine administration and total parenteral nutrition, but bowel symptoms were exacerbated and C‐reactive protein level was elevated after a polymeric diet was started. Prednisolone 30 mg/day was started in addition to total parenteral nutrition, but hematochezia and elevated serum C‐reactive protein level persisted, and she was referred to our hospital. She had about four bowel movements per day with fresh bleeding at the time of admission. Total parenteral nutrition and oral mesalazine were continued. The dose of oral prednisolone was increased from 15 mg/day to 40 mg/day. However, the frequency of bowel movements did not decrease and C‐reactive protein level continued to exceed 1.5 mg/day. Mesalazine enemas were begun on 23 January 2001, and were effective in improving hematochezia and serum C‐reactive protein. Both radiologic and endoscopic examinations revealed remarkable improvement.     

双歧杆菌三联活菌联合美沙拉嗪治疗溃疡性结肠炎临床研究

目的探讨双歧杆菌三联活菌联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对患者T淋巴细胞亚群和血清纤维蛋白原(Fib)水平的影响。方法选取医院2018年3月至2020年3月收治的溃疡性结肠炎患者102例,随机分为观察组和对照组,各51例。两组患者均口服美沙拉嗪肠溶片,观察组患者加服双歧杆菌三联活菌胶囊,均连续治疗4周。结果观察组总有效率为88.24%,明显高于对照组的70.59%(P<0.05);治疗后,观察组患者CD3+及CD4+细胞阳性率,CD4+/CD8+均明显高于对照组,CD8+细胞阳性率和C反应蛋白(CRP)、白细胞介素1β(IL-1β)、白细胞介素8(IL-8)水平均明显低于对照组(P<0.05);观察组治疗第1,2,4周的Fib水平均明显低于对照组(P<0.05);观察组与对照组不良反应发生率相当(17.65%比11.76%,P>0.05)。结论双歧杆菌三联活菌联合美沙拉嗪治疗溃疡性结肠炎,能明显改善患者的T淋巴细胞亚群和血清Fib水平,降低炎性因子水平。     

涩肠青黛散联合美沙拉嗪对溃疡性结肠炎患者炎症因子及氧化应激的影响

目的:观察涩肠青黛散联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对炎症因子及氧化应激的影响。方法:将74例患者按随机数字表法分为对照组和治疗组,每组37例。对照组采用美沙拉嗪治疗,治疗组在对照组治疗基础上加用涩肠青黛散治疗,治疗4周后,测定并记录两组患者白细胞介素-6(interleukin-6,IL-6)、白细胞介素-8(interleukin-8,IL-8)及肿瘤坏死因子-α(tumor necrosis facto-α,TNF-α)水平,超氧化物歧化酶(superoxide dismutase,SOD)、丙二醛(malondialdehyde,MDA)水平,生活质量,同时比较临床疗效和不良反应状况。结果:对照组有效率为70.27%,治疗组有效率为91.89%,两组比较差异有统计学意义(P0.05);治疗组治疗后IL-6、IL-8、TNF-α水平较低,SOD、MDA水平较高,生活质量明显改善,两组比较,差异均有统计学意义(P0.05)。结论:涩肠青黛散联合美沙拉嗪能有效降低溃疡性结肠炎患者IL-6、IL-8、TNF-α水平,提高SOD、MDA水平,临床疗效显著。     

The role of Budesonide-MMX in active ulcerative colitis

Traditional corticosteroids represent a well-established and effective treatment for active ulcerative colitis (UC). However, the severity of their systemic side effects, led in recent years to look for new steroid molecules that could reduce them, maximizing the anti-inflammatory activity. Budesonide has been one of the most studied steroid compounds and it has been approved for the treatment of mild to moderate active Crohn's disease (CD). In order to extend the release until the distally located inflammation, budesonide has been coupled with a controlled delivery system, called Multi-Matrix system (MMX^®), already successfully tested with oral mesalazine for the treatment of distal UC. After in vitro and in vivo models, the efficacy of Budesonide-MMX has been investigated in active UC with a first small phase II study, and partially encouraging results. This article will review the evidences on the use of budesonide in inflammatory bowel diseases and will discuss the role of Budesonide-MMX in active UC nowadays.     

美沙拉嗪颗粒联合双歧三联活菌胶囊对溃疡性结肠炎患者血清SOD、MDA的影响

目的探讨美沙拉嗪颗粒(艾迪莎)与双歧三联活菌胶囊(培菲康)联合治疗对溃疡性结肠炎(UC)患者血清中丙二醛(MDA)浓度和超氧化物歧化酶(SOD)活力的影响。方法 38例UC患者随机分为两组:对照组和治疗组,每组各19例。对照组给予美沙拉嗪颗粒(1.0 g/次,4次/d),治疗组在此基础上加用双歧三联活菌胶囊(420 mg/次,3次/d),疗程均为2个月。比较治疗前后UC患者血清中MDA浓度和SOD活力,同时对治疗前后两组患者临床疗效进行评价。结果治疗组和对照组MDA浓度均较治疗前降低(P<0.05),SOD活力较治疗前上升(P<0.05)。两组治疗前后差值比较,差异也有统计学意义(P<0.05)。治疗组总有效率高于对照组(P<0.05)。结论美沙拉嗪颗粒联合双歧三联活菌胶囊治疗UC较单独使用美沙拉嗪颗粒可更明显地降低MDA的水平,升高SOD活力。     

Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial

BACKGROUND: Collagenous colitis (CC) and lymphocytic colitis (LC) are chronic inflammatory diseases of the colon with a benign and sometimes relapsing course. Frequency among patients with chronic diarrhea and normal looking colonoscopy is around 10-15%. To date, treatment of CC and LC is not well defined. Data about these conditions are mostly derived from retrospective studies. The aim of the present study was to evaluate the response to treatment and the clinical course of CC and LC in a large group of patients prospectively diagnosed. METHODS AND RESULTS: A total of 819 patients underwent a colonoscopy because of chronic watery diarrhea and among them we found 41 patients with LC and 23 with CC. These patients were later randomized and assigned to treatment with mesalazine or mesalazine + cholestyramine for 6 months. Fifty-four patients (84.37%) had resolved diarrhea in less than 2 weeks. After 6 months a colonoscopy with biopsies was repeated. Clinical and histological remission was achieved in 85.36% of patients with LC and in 91.3% with CC, with a better result in patients with CC treated with mesalazine + cholestyramine. During a mean period of 44.9 months, 13% of patients relapsed; four with LC and three with CC. They were retreated for another 6 months. At the end of this period one patient with CC was still symptomatic and persistence of CC was confirmed at histology. CONCLUSIONS: Treatment with mesalazine seems to be an effective therapeutic option for LC to date, while mesalazine + cholestyramine seems to be more useful in the treatment of CC.